Emerging angiogenesis inhibitors for non-small cell lung cancer.
Authors: Malapelle U, Rossi A Abstract INTRODUCTION: Angiogenesis represent a complex process crucial during embryo development, wound healing, and collateral formation for improved organ perfusion. Numerous stimulatory and inhibitory pathways through their balance regulate angiogenesis and vascular homeostasis. Targeting the pathways implicated in the regulation of angiogenesis and neo-angiogenesis play an important role in cancers research, treatment and patients' outcome. Antiangiogenic strategies, including monoclonal antibodies binding vascular endothelial growth factor (VEGF) or the corresponding receptor and...
Source: Expert Opinion on Emerging Drugs - May 17, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for essential thrombocythemia.
Authors: Masarova L, Verstovsek S Abstract INTRODUCTION: Despite our recent progress in the understanding of essential thrombocythemia (ET) pathogenesis, the therapeutic management of this disease has remained largely unchanged in the past decades. Treatment has mostly focused on decreasing the risk of complications, especially prevention of thrombotic or hemorrhagic events. Areas covered: Over recent years, the treatment options of ET have been expanding with some novel agents on the horizon. The classes of agents described in this review include targeted and immunomodulatory agents, such as JAK1/2 inhibitors, int...
Source: Expert Opinion on Emerging Drugs - May 7, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for progressive supranuclear palsy.
Authors: Giagkou N, Stamelou M Abstract INTRODUCTION: Progressive supranuclear palsy (PSP) is a common cause of atypical parkinsonism and a rapidly progressive disease that greatly burdens both patients and caregivers. Drugs with disease-modifying potential, targeting mechanisms implicated in the disease's pathogenesis are currently tested in Phase 1 and 2 trials. If proven efficacious, these compounds might provide substantial benefits not only to patients with PSP, but to patients with other tauopathies as well. Areas covered: Drugs in Phase 1 and 2 trials in PSP, and Phase 2 trials in other tauopathies (Alzheime...
Source: Expert Opinion on Emerging Drugs - April 23, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging PEGylated non-biologic drugs.
Authors: Park EJ, Choi J, Lee KC, Na DH Abstract INTRODUCTION: PEGylation is a well-established technology for improving the therapeutic value of drugs by attaching polyethylene glycol (PEG). The first PEGylated enzyme products appeared on the market in the early 1990s; currently, more than 18 PEGylated products have been approved by Food and Drug Administration, which encompass various classes of drug molecules, such as enzymes, interferons, granulocyte colony-stimulating factors, hormones, antibody fragments, coagulation factors, oligonucleotide aptamers, synthetic peptides, and small organic molecules. Areas cov...
Source: Expert Opinion on Emerging Drugs - April 10, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Factor XI Inhibition fulfilling the optimal expectations for ideal anticoagulation.
Authors: Székely O, Borgi M, Lip GYH Abstract INTRODUCTION: Thromboembolic diseases are leading cause of mortality accounting for an estimated 1 in 4 deaths all over the world. Anticoagulation remains the mainstay of prevention and treatment of venous thromboembolic disorders. Conventional anticoagulants have been efficiently used over the last decades, but their clinical use encounters safety and convenience issues. To overcome these limitations, research have focused on development of new targets for anticoagulation leading to a relatively new class of drugs, non-vitamin K antagonist oral anticoagulants, s...
Source: Expert Opinion on Emerging Drugs - March 10, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

What role do pharmaceuticals play in the treatment of Peyronie's disease and is there a need for new emerging drugs?
Authors: Milenkovic U, Ilg MM, Cellek S, Albersen M PMID: 30845848 [PubMed - as supplied by publisher] (Source: Expert Opinion on Emerging Drugs)
Source: Expert Opinion on Emerging Drugs - March 10, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for the treatment of hypercholesterolemia.
Authors: Bove M, Cicero AFG, Borghi C Abstract Introduction Despite the consolidated role of statins and ezetimibe to treat hypercholesterolemia, often the desirable Low-Density-Lipoprotein-cholesterol (LDL-C) values are not achieved, with a consequent increase of the residual cardiovascular (CV) risk. Areas covered In this review, we summarize the main pharmacological characteristics of new lipid-lowering drugs, such as Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) Inhibitors, Cholesteryl-Ester-Transfer Protein inhibitors, Microsomal Triglyceride Transfer Protein inhibitors, ATP citrate lyase inhibitors, A...
Source: Expert Opinion on Emerging Drugs - March 8, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for the treatment of Clostridium difficile.
Authors: Cammarota G, Gallo A, Ianiro G, Montalto M Abstract Introduction Clostridium difficile, or Clostridioides difficile, (C difficile) infection represents the most common cause of healthcare-associated infection. Over the last decades, the incidence and severity of C difficile infection is rapidly increasing, with a significant impact on morbidity and mortality, and burden on health care system. Orally administered vancomycin and fidaxomicin are the therapeutic options of choice for initial C difficile infection and fecal microbiota transplant for the recurrence infection. Furthermore, in recent years several...
Source: Expert Opinion on Emerging Drugs - March 8, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Standard treatment and emerging drugs for managing synovial sarcoma: adult's and pediatric oncologist perspective.
Authors: Baldi GG, Orbach D, Bertulli R, Magni C, Sironi G, Ferrari A Abstract INTRODUCTION: in this review we discuss the standard of care for both pediatric and adult synovial sarcoma (SS), the prognostic differences between them, and the treatments available for localized and advanced diseases. We also overview the biology and the recent drugs under consideration in clinical trials on SS. Areas covered: we focus on new targeted therapies being investigated for advanced SS, especially anti-angiogenic drugs, and immunotherapy. We review all the published data and ongoing trials dedicated to SS or to soft tissue sa...
Source: Expert Opinion on Emerging Drugs - March 8, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for treating the acute respiratory distress syndrome.
Authors: Shaw TD, McAuley DF, O'Kane CM Abstract Introduction The acute respiratory distress syndrome (ARDS) is a common and catastrophic condition, with a high mortality rate and economic burden on society. Despite 50 years of study, there is no specific pharmacological therapy for ARDS. Areas covered This review outlines the definitions, epidemiology, risk factors and pathophysiology of ARDS. The priority of developing a clinically-relevant model for ARDS to test pre-clinical candidates is discussed, together with the limitations of current models. The scientific rationale of emerging therapeutic candidates is ou...
Source: Expert Opinion on Emerging Drugs - March 8, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for EGFR-mutated non-small cell lung cancer.
Authors: Sukrithan V, Deng L, Barbaro A, Cheng H Abstract INTRODUCTION: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent the standard of care for patients with metastatic non-small-cell lung cancer (NSCLC) harboring sensitizing EGFR mutations. However, these agents are associated with inevitable treatment resistance. Newer generations of TKIs are under development that may prevent or overcome resistance and enhance intracranial activity. Areas covered: In this review, we will discuss newer generations of EGFR TKIs for EGFR-mutated NSCLC. We will also address resistance mutations a...
Source: Expert Opinion on Emerging Drugs - December 22, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

An update: emerging drugs for tinnitus.
Authors: Cederroth CR, Dyhrfjeld-Johnsen J, Langguth B Abstract INTRODUCTION: During the last decade, a number of candidate drugs for the treatment of tinnitus have emerged with the hope of alleviating the burden of millions of sufferers with a persisting ringing in their ears. Knowledge of the pathophysiologic mechanisms has progressed remarkably in the recent years, which has led to the identification of potential new drug targets for the treatment of tinnitus. However, pharmacologic interventions are still limited. Areas covered: In this editorial results from recent Phase 3 and Phase 2a trials investigating the...
Source: Expert Opinion on Emerging Drugs - December 15, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Novel therapeutic approaches in primary hyperoxaluria.
Authors: Weigert A, Martin-Higueras C, Hoppe B Abstract INTRODUCTION: Currently, three types of primary hyperoxaluria (PH I-III) are known, all based on different gene-mutations affecting the glyoxylate metabolism in the liver. Disease hallmark is an increased endogenous oxalate production and thus massively elevated urinary excretion of oxalate and other type-specific metabolites. Hyperoxaluria induces the formation of calcium-oxalate kidney stones and/or nephrocalcinosis. In addition to that, a chronic inflammasome activation by hyperoxaluria per se, often leads to an early deterioration of kidney function, regul...
Source: Expert Opinion on Emerging Drugs - December 13, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

An update on emerging drugs for the treatment of erectile dysfunction.
Authors: Milenkovic U, Campbell J, Roussel E, Albersen M Abstract INTRODUCTION: Erectile dysfunction is an extremely frequent and extensively studied condition, currently affecting the lives of tens of millions of men around the globe. The extensive knowledge of its pathophysiology has led to the development of phosphodiesterase 5-inhibitors, which can facilitate sexual intercourse in a large number of patients. However, an ever-increasing number of patients is unresponsive to these drugs due to underlying comorbidities or previous surgery. Different molecular pathways need to be addressed to provide treatment for ...
Source: Expert Opinion on Emerging Drugs - December 7, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for the treatment of Dravet syndrome.
Authors: Brigo F, Striano P, Balagura G, Belcastro V Abstract INTRODUCTION: Dravet syndrome (DS) is an early-onset genetic developmental epileptic encephalopathy characterized by multiple seizure types which are refractory to antiseizure medication. There is an unmet need for effective and tolerable drugs to control different seizure types in DS types, with the aim of improving quality of life and preventing neurological impairment. Areas covered: Narrative review of efficacy and tolerability of fenfluramine, cannabidiol (CBD), verapamil and modulators of serotonin signaling pathways (lorcaserin or trazodone) in th...
Source: Expert Opinion on Emerging Drugs - November 30, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for migraine treatment: an update.
Authors: Lambru G, Andreou AP, Guglielmetti M, Martelletti P Abstract INTRODUCTION: Migraine is a very frequent and disabling neurological disorder. The current treatment options are old, generally poorly tolerated and not migraine-specific, reflecting the low priority of migraine research and highlighting the vast unmet need in its management. Areas covered: Advancement in the understanding of migraine pathophysiological mechanisms and identification of novel potentially meaningful targets have resulted in a multitude of emerging acute and preventive treatments. Here we review the known putative migraine pathophys...
Source: Expert Opinion on Emerging Drugs - November 30, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer.
Authors: Batra A, Winquist E Abstract Introduction Disease progression despite androgen suppression defines lethal castration-resistant prostate cancer (CRPC). Most of these cancers remain androgen receptor (AR)-signalling dependent. Therapy for metastatic CRPC includes abiraterone acetate, enzalutamide, docetaxel, cabazitaxel, sipuleucel-T, and radium-223. However, survival remains modest for men with progressive disease despite AR-targeted therapy and docetaxel, and therefore novel treatments are needed. Areas covered Recent evidence of genomic heterogeneity and sensitivity to PARP inhibitors supports investigati...
Source: Expert Opinion on Emerging Drugs - November 15, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Disease-modifying Drugs in Osteoarthritis: Current Understanding and Future Therapeutics.
Authors: Oo WM, Yu SC, Daniel MS, Hunter DJ Abstract INTRODUCTION: Osteoarthritis (OA) is a leading cause of pain and disability among adults with a current prevalence of around 15% and a predicted prevalence of 35% in 2030 for symptomatic OA. It is increasingly recognized as a heterogeneous multi-faceted joint disease with multi-tissue involvement of varying severity. Current therapeutic regimens for OA are only partially effective and often have significant associated toxicities. There are no disease-modifying drugs approved by the regulatory bodies. Areas covered: We reviewed the opportunities within key OA path...
Source: Expert Opinion on Emerging Drugs - November 13, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

An update: emerging drugs to treat squamous cell carcinomas of the head and neck.
Authors: Lee YS, Johnson DE, Grandis JR Abstract INTRODUCTION: Subsequent to the 2006 FDA approval of cetuximab, a variety of molecular targeting agents have been evaluated in head and neck squamous cell carcinoma (HNSCC). The treatment outcomes of recurrent and/or metastatic (R/M) HNSCC, in particular, remain dismal. The 2016 FDA approval of PD-1 immune checkpoint inhibitors has expanded the treatment options for R/M HNSCC, and highlights the potential for immune-based therapies. Areas covered: We will review the clinical application of EGFR-targeted agents, alone and in combination with other drugs. Molecular tar...
Source: Expert Opinion on Emerging Drugs - November 2, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging PARP inhibitors for treating breast cancer.
Authors: Robert M, Patsouris A, Frenel JS, Gourmelon C, Augereau P, Campone M Abstract INTRODUCTION: Some breast cancers harbor defects in DNA repair pathways, including BRCA1 and BRCA2 mutations, leading to a genomic instability. Compromised DNA-damage repair response is found in 11 to 42% of triple negative breast cancers, with a frequency varying according to family history and ethnicity. The oral PARP inhibitors are a promising strategy in breast cancer exploiting Homologous Deficient Recombination deficiency (HRD) by a synthetic lethal approach. Several PARP inhibitors have currently reached early phase trials...
Source: Expert Opinion on Emerging Drugs - September 27, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors.
Authors: Spagnuolo A, Maione P, Gridelli C PMID: 30251885 [PubMed - as supplied by publisher] (Source: Expert Opinion on Emerging Drugs)
Source: Expert Opinion on Emerging Drugs - September 27, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Expert opinion on existing and developing drugs to treat female sexual dysfunction.
Authors: Miller MK, Smith JR, Norman JJ, Clayton AH Abstract INTRODUCTION: Female sexual dysfunction (FSD) is a highly prevalent, yet commonly underdiagnosed and undertreated condition. This paper reviews the diagnostic terminology for FSD, and basic sexual physiology in women. The Food and Drug Administration (FDA) approved drugs for FSD are discussed, followed by investigational drugs for FSD currently in phase 2 or 3 clinical trials, reasons for failure of drug development, and potential future drug targets. Areas Covered: A literature review was conducted for available treatments for FSD: flibanserin, estrogen,...
Source: Expert Opinion on Emerging Drugs - September 27, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for focal epilepsy.
EMERGING DRUGS FOR FOCAL EPILEPSY. Expert Opin Emerg Drugs. 2018 Sep 25;: Authors: Mula M Abstract INTRODUCTION: Epilepsy is one of the most serious neurological conditions, affecting almost 50 million people around the world. Despite more than 20 antiepileptic drugs (AEDs) available, seizures are still uncontrolled in one third of patients. Areas covered: The present paper reviews current compounds in preclinical and clinical development for the treatment of focal epilepsies and new potential molecular targets recently identified. Expert Opinion: 1OP-2198, Cannabidavirin, Everolimus, FV-082, Ganaxolon...
Source: Expert Opinion on Emerging Drugs - September 27, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Expert opinion on emerging urate-lowering therapies.
Authors: Stamp LK, Merriman TR, Singh JA Abstract INTRODUCTION: There has been a resurgence in gout therapeutics in the last decade, not only for the management of gout flares, but also for the treatment of hyperuricemia. This editorial summarizes new, emerging therapies for people with gout. Areas Covered: We review several new therapies for gout, including those that are focused on lowering serum urate (levotofisopam, ulodesine, verinurad, merbarone, KUX-1151, UR-1102, FYU-981, SEL-212), or treating gout flares (canakinumab, bucillamine) or both (arhalofenate, diacerein). Expert Opinion: Among therapies with both...
Source: Expert Opinion on Emerging Drugs - September 26, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging antibacterial and antiviral drugs for treating respiratory tract infections.
Authors: Mantero M, Rogliani P, Cazzola M, Blasi F, Di Pasquale M Abstract INTRODUCTION: Management of LRTI is becoming more frequently challenging since the emergence of multidrug resistance bacteria and the increase of severe viral infection, reducing the number of available effective drugs. The clinical evaluation of new therapeutic associations is mandatory to cope with the increases in resistance, in association with better infection control and antimicrobial policies. Areas covered: We searched Pubmed in English language of phase I, II, III clinical trials and approved treatments for LRTI, between 2006 and 20...
Source: Expert Opinion on Emerging Drugs - July 25, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging Drugs for Eosinophilic Esophagitis.
Authors: Pesek RD, Gupta SK Abstract INTRODUCTION: Eosinophilic esophagitis (EoE) is rare but incidence and prevalence is increasing. EoE is characterized by eosinophilic inflammation of the esophagus causing gastrointestinal symptoms such as abdominal pain, vomiting, reflux, dysphagia, and food impactions. If untreated, remodeling and fibrosis of the esophagus can occur and stricture formation may result. Current treatment options are limited to food-restriction diets or medications including proton pump inhibitors (PPIs) or swallowed corticosteroids. Significant progress has been made in understanding the underly...
Source: Expert Opinion on Emerging Drugs - June 2, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma.
Authors: Rodgers TD, Reagan PM Abstract INTRODUCTION: The B-cell receptor (BCR) pathway is a crucial aspect of mature lymphocytes and is maintained in B-cell neoplasms. Many small module inhibitors targeting kinases within the BCR pathway are approved, with others in development, offering alternative treatment options to standard chemoimmunotherapy. Areas Covered: This review covers both approved inhibitors and investigational inhibitors of spleen tyrosine kinase (SYK), Bruton's tyrosine kinase (BTK), and phosphoinositide-3-kinase (PI3K) in the treatment of B-cell lymphomas. To collect relevant articles, a literatu...
Source: Expert Opinion on Emerging Drugs - May 25, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer.
Authors: Crijnen J, de Reijke TM Abstract INTRODUCTION: Bladder cancer (BC) is a severe health burden: it is the fifth most common malignancy in the world and has high recurrence and progression rates. Standard treatment starts with TURB followed by intravesical chemotherapy with Mitomycin C or immunotherapy with BCG. However, successful management still remains a challenge, because approximately 30% of patients have recurrence or progression within 5 years, and treatment has considerable side effects. Anticipating on the upcoming BCG shortage emphasizes, moreover, the necessity to develop and study novel treatment...
Source: Expert Opinion on Emerging Drugs - May 9, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging Reverse Transcriptase Inhibitors for HIV-1 Infection.
Authors: Rai MA, Pannek S, Fichtenbaum CJ Abstract INTRODUCTION: There are 36.7 million people living with HIV with 20.9 million having access to antiretroviral therapy (ART). Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) remain the 'backbone' of ART. However, the currently available nine NRTIs and five non-nucleoside reverse transcriptase inhibitors (NNRTIs) have significant side effects and resistance profiles. Areas covered: We summarize the mechanisms of resistance and other limitations of the existing NRTIs/NNRTIs. GS-9131, MK-8591, Elsulfavirine and Doravirine are four new agents that are fur...
Source: Expert Opinion on Emerging Drugs - May 9, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis.
Authors: Aryal S, Nathan SD Abstract Introduction Idiopathic pulmonary fibrosis is a chronic, progressive fibrotic lung disease of unknown etiology associated with a high morbidity and mortality. The hallmark of the disease is impaired healing after alveolar epithelial injury in the setting of a genetic predisposition. Development of two new drugs has changed the landscape of the treatment of IPF but more work is needed to improve outcomes and improve survival. Areas Covered The development of two antifibrotic agents, nintedanib and pirfenidone has been an exciting landmark in the treatment of IPF. Current research...
Source: Expert Opinion on Emerging Drugs - May 3, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for primary progressive multiple sclerosis.
Authors: Narayan RN, Forsthuber T, Stüve O Abstract INTRODUCTION: While substantial progress has been made in the past three decades in treating relapsing forms of multiple sclerosis, the identification of effective therapies for progressive forms of multiple sclerosis (MS) has remained mostly elusive, and remains a priority and challenge for the global MS community. Although axonal degeneration in a setting of demyelination, failure of remyelination, neuronal death, axonal energy failure have been implicated in this disease process, a more complete understanding of the mechanisms involved in the pathogenesis ...
Source: Expert Opinion on Emerging Drugs - April 15, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

PARP inhibitors for Homologous Recombination-Deficient Prostate Cancer.
Authors: Christenson ES, Antonarakis ES Abstract INTRODUCTION: Prostate adenocarcinoma represents a leading cause of cancer-related mortality. Increased emphasis on understanding the molecular basis of prostate cancer has identified a substantial burden of homologous recombination (HR) pathway mutations, which are enriched in castrate-resistant disease. This discovery has yielded novel therapeutic opportunities. Areas covered: We will discuss the treatment of castrate-resistant prostate cancer (CRPC), with a focus on the use of poly (ADP-ribose) polymerase (PARP) inhibitors in this space. Evidence for use in HR-def...
Source: Expert Opinion on Emerging Drugs - March 30, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging growth factor receptor antagonists for ovarian cancer treatment.
Authors: Bonilla L, Oza A, Lheureux S Abstract INTRODUCTION: Epithelial Ovarian Cancer (EOC) is the most lethal gynecological malignancy. EOC outcomes remain unsatisfactory despite aggressive surgical approach, disease chemo-sensitivity and recent introduction of agents targeting angiogenesis and tumour genome instability. Advances in EOC research have allowed for a tailored treatment approach and accelerated development of novel treatments strategies from bench to bed side, anticipated to improve patient outcomes. Areas covered: Comprehensive review of growth factor receptor antagonists for EOC treatment currently...
Source: Expert Opinion on Emerging Drugs - March 13, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging pharmacotherapies for the treatment of atrial fibrillation.
Authors: Capucci A, Cipolletta L, Guerra F, Giannini I Abstract INTRODUCTION: The main aim of current research on the field of atrial fibrillation (AF) treatment is to find new antiarrhythmic drugs with less side effects. Areas covered: Dronedarone and vernakalant showed promising result in term of efficacy and safety in selected patients. Ranolazine and colchicine are obtaining a role as a potential antiarrhythmic drug. Ivabradine is used in experimental studies for the rate control of AF. Moreover, new compounds (vanoxerine, moxonidine, budiodarone) are still under investigation. Monoclonal antibodies or selectiv...
Source: Expert Opinion on Emerging Drugs - March 7, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging treatment options for uterine fibroids.
Authors: Donnez J, Arriagada P, Donnez O, Dolmans MM Abstract INTRODUCTION: Uterine fibroids (also known as leiomyomas or myomas) are the most common form of benign uterine tumors. Current management strategies involve mainly surgical interventions, but the choice of treatment is guided by patient age and desire to preserve fertility or avoid 'radical' surgery such as hysterectomy. Areas covered: There is growing evidence of the crucial role of progesterone pathways in the pathophysiology of uterine fibroids, leading to increasing use of selective progesterone receptor modulators (SPRMs) such as ulipristal acetate....
Source: Expert Opinion on Emerging Drugs - March 2, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging Alternatives to Tyrosine Kinase Inhibitors for Treating Chronic Myeloid Leukemia.
Authors: Kavanagh S, Nee A, Lipton JH Abstract INTRODUCTION: BCR-ABL-directed tyrosine kinase inhibitors (TKIs) have revolutionised therapy for chronic myeloid leukemia. However, despite the availability and efficacy of this class of agents, lifelong treatment is still required in a significant proportion of patients Areas Covered: We give an overview of the currently available BCR-ABL-directed TKIs and other conventional therapies for CML. We proceed to review the current market and some of the scientific rationale for new drug development before outlining a number of novel therapies, considered broadly as immunot...
Source: Expert Opinion on Emerging Drugs - February 28, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

"Emerging drugs for the treatment of Myelofibrosis".
"Emerging drugs for the treatment of Myelofibrosis". Expert Opin Emerg Drugs. 2018 Feb 26;: Authors: Shreenivas A, Mascarenhas J Abstract INTRODUCTION: Myelofibrosis (MF) is a Philadelphia chromosome-negative myeloproliferative neoplasm (MPN). It can be sub-categorized into primary myelofibrosis, post polycythemia vera myelofibrosis and post essential thrombocythemia myelofibrosis. MF is a life-threatening hematologic malignancy characterized by dysregulation of the Janus associated kinase (JAK)/signal transducer and activator of transcription (STAT) signaling network and a heightened inflamm...
Source: Expert Opinion on Emerging Drugs - February 28, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for the treatment of axial spondyloarthritis.
Authors: Rademacher J, Poddubnyy D Abstract INTRODUCTION: The treatment of axial spondyloarthritis(axSpA) has been for nearly 15 years constricted to non-steroidal antirheumatic drugs and TNFα inhibitors. With the approval of secukinumab, a drug targeting the interleukin(IL)-17 axis became available. Nonetheless, an unmet need for further emerging therapeutic options remains. Areas covered. This review summarizes the recent and ongoing clinical trials with novel drugs in axSpA. Besides secukinumab, further therapeutics directed against the IL-17A (e.g., ixekizumab) as well as the dual IL-17A and F inhibitor b...
Source: Expert Opinion on Emerging Drugs - February 27, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging molecular target antagonists for the treatment of biliary tract cancer.
Authors: Lombardi P, Marino D, Fenocchio E, Chilà G, Aglietta M, Leone F Abstract INTRODUCTION: Biliary tract cancers (BTCs) are a heterogeneous group of cancers, characterized by low incidence but poor prognosis. Even after complete surgical resection for early stage, relapse is frequent and the lack of effective treatments contributes to the dismal prognosis. To date, the only standard treatment in first-line is cisplatin/gemcitabine combination, whereas no standard in 2nd-line has been defined. Hence, the current goal is to better understand the biology of BTCs, discovering new treatment methods and impro...
Source: Expert Opinion on Emerging Drugs - February 24, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for alopecia areata: jak inhibitors.
EMERGING DRUGS FOR ALOPECIA AREATA: JAK INHIBITORS. Expert Opin Emerg Drugs. 2018 Feb 21;: Authors: Iorizzo M, Tosti A Abstract INTRODUCTION: Alopecia Areata is a common form of non-scarring hair loss that usually starts abruptly with a very high psychological impact. Due to the still not completely understood etiopathogenesis, at present there is no treatment that can induce a permanent remission and there is no drug approved for the treatment of this disorder. Areas covered: Leading existing treatment are briefly overviewed and then ongoing research on Janus Kinases Inhibitors is discussed, reviewing...
Source: Expert Opinion on Emerging Drugs - February 22, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

An update on new and emerging therapies for cystic fibrosis.
Authors: Hudock KM, Clancy JP Abstract INTRODUCTION: Cystic fibrosis (CF) is a genetic disorder that results in a multi-organ disease with progressive respiratory decline that ultimately leads to premature death. CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which codes for the CFTR anion channel. Established CF treatments target downstream manifestations of the primary genetic defect, including pulmonary and nutritional interventions. Areas covered: CFTR modulators are novel therapies that improve the function of CFTR, and have been approved in the past five year...
Source: Expert Opinion on Emerging Drugs - December 23, 2017 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

An update on emerging drugs for fibromyalgia treatment.
AN UPDATE ON EMERGING DRUGS FOR FIBROMYALGIA TREATMENT. Expert Opin Emerg Drugs. 2017 Dec 18;: Authors: Atzeni F, Gerardi MC, Masala IF, Alciati A, Batticciotto A, Sarzi-Puttini P Abstract INTRODUCTION: Fibromyalgia (FM) is a chronic disorder whose symptoms of pain, fatigue, sleep disturbances and depression have a devastating effect on patients' lives as it limits their ability to engage in everyday working and social activities, and make it difficult to maintain normal relationships with family, friends and employers. None of the currently available drugs are fully effective against the whole spectru...
Source: Expert Opinion on Emerging Drugs - December 20, 2017 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging first line treatment options for bladder cancer: A review of phase II and III therapies in the pipeline.
Authors: Jamy O, Sonpavde G Abstract INTRODUCTION: The treatment of urothelial carcinoma (UC) had remained unchanged for several years until the recent FDA approval of immune checkpoint inhibitors (CPIs) in the salvage setting. Novel dual CPI-CPI and CPI-chemotherapy combinations are now being investigated aggressively as first line therapy for metastatic disease. Areas Covered: We discuss the recent insights into the tumor biology of UC, which may impact the prognosis as well as assist in developing precision medicine. This is followed by an overview of existing treatment including conventional chemotherapy as wel...
Source: Expert Opinion on Emerging Drugs - December 13, 2017 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for the treatment of gastrointestinal stromal tumour.
Authors: Kasireddy V, von Mehren M Abstract INTRODUCTION: Tyrosine kinase inhibitors (TKIs) have transformed the treatment landscape for patients with gastrointestinal stromal tumors (GIST). Unfortunately, resistance to the currently approved TKIs poses a huge challenge, and patients are in need of additional therapeutic options. Fortunately, many novel therapeutic approaches are being tested in treatment of GIST to overcome resistance to the approved TKIs Areas Covered: We performed an extensive literature (PUBMED) search to identify emerging drugs being tested in treatment of GIST in early phase clinical trials. ...
Source: Expert Opinion on Emerging Drugs - December 2, 2017 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Medications for substance use disorders (SUD): Emerging approaches.
Authors: Butelman ER, Kreek MJ Abstract INTRODUCTION: Substance use disorders are a group of chronic relapsing disorders of the brain, which have massive public health and societal impact. In some disorders (e.g., heroin/prescription opioid addictions) approved medications have a major long-term benefit. For other substances (e.g., cocaine, amphetamines and cannabis) there are no approved medications, and for alcohol there are approved treatments, which are not in wide usage. Approved treatments for tobacco use disorders are available, and novel medications are also under study. Areas covered: Medication-based appr...
Source: Expert Opinion on Emerging Drugs - October 24, 2017 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.
Authors: Monaco TJ, Hanania NA Abstract INTRODUCTION: Chronic obstructive pulmonary disease (COPD), characterized by persistent and partially reversible airflow obstruction, is a leading cause of morbidity and mortality worldwide. Long-acting inhaled bronchodilators form the backbone for the maintenance therapy for this disease. The ultra-long-acting β2-agonists (ultra-LABAs) represent novel pharmacologic agents with interesting potential benefits as stand-alone therapy or in combination with other therapies for the treatment of COPD. Areas covered: In this review, we will focus newly developed ultra-LABAs, de...
Source: Expert Opinion on Emerging Drugs - September 6, 2017 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging interleukin receptor antagonists for the treatment of asthma.
Authors: Al Efraij K, FitzGerald JM Abstract INTRODUCTION: Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. Most patients with asthma can be well-controlled with inhaled corticosteroids and, if necessary, the addition of a long-acting beta agonist. Despite these therapies, 5% to 10% of patients with asthma have severe, uncontrolled asthma. Selecting patients based on peripheral eosinophil counts and a history of exacerbations has led to significant decreases in exacerbations and an improvement in asthma control with medications that target IL-4, IL-5 and IL-13/. Areas covered...
Source: Expert Opinion on Emerging Drugs - August 25, 2017 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

An update on the developing mitotic inhibitors for the treatment of non-small cell carcinoma.
Authors: Sacco PC, Gridelli C Abstract INTRODUCTION: Mitosis is necessary to sustain life and is followed immediately by cell division into two daughter cells. Microtubules play a key role in the formation of the mitotic spindle apparatus and cytokinesis at the end of mitosis. Various anti-microtubule agents such as taxanes and vinca alkaloids are widely used in the treatment of advanced non-small cell lung cancer (NSCLC) but their use is associated with hematologic toxicity profile, acquired resistance and hypersensitivity reactions. Areas covered: The Nab-paclitaxels are the more recent antimitotic agents approve...
Source: Expert Opinion on Emerging Drugs - August 25, 2017 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for the treatment of benign prostatic hyperplasia.
Authors: Thomas DB, Chughtai B, Kini M, Te A Abstract INTRODUCTION: Benign prostatic hyperplasia (BPH) is a common condition affecting over 50% of men as they reach their 5(th) decade of life. This leads to a number of sequelae such as lower urinary tract symptoms, urinary retention and a decrease in quality of life. Currently, the available treatments for BPH are alpha blockers and 5-alpha reductase inhibitors. Clinical studies have demonstrated these medical options are effective in alleviating a patient's symptoms, however there are a number of side effects. There is a paucity of information regarding long-term ...
Source: Expert Opinion on Emerging Drugs - August 24, 2017 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging antibody-drug conjugates for treating lymphoid malignancies.
Authors: Wolska-Washer A, Robak P, Smolewski P, Robak T Abstract BACKGROUND: Antibody-drug conjugates (ADC) are monoclonal antibodies (Mabs) attached to biologically active drugs through specialized chemical linkers. They deliver and release cytotoxic agents at the tumor site, reducing the likelihood of systemic exposure and therefore toxicity. These agents should improve the potency of chemotherapy by increasing the accumulation of the cytotoxic drug within or near the neoplastic cells with reduced systemic effects. Areas covered and methods: A literature review was conducted using the MEDLINE database, PubMed, fo...
Source: Expert Opinion on Emerging Drugs - August 11, 2017 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research